ATRX-Deficient High-Grade Glioma Cells Exhibit Increased Sensitivity to RTK and PDGFR Inhibitors

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• High-grade gliomas, including glioblastoma (GBM), have a poor prognosis due to limited treatment options.
• Mutations in the ATRX gene are common in high-grade gliomas, suggesting it as a potential therapeutic target.

Purpose of the Study:

• To identify FDA-approved drugs effective against ATRX-deficient high-grade glioma cells.
• To evaluate the efficacy of combining receptor tyrosine kinase inhibitors (RTKi) with temozolomide (TMZ) in ATRX-mutated gliomas.

Main Methods:

• Screening of FDA-approved drugs for toxicity in ATRX-deficient glioma cells.
• Assessment of cellular toxicity of multi-targeted RTK and PDGFR inhibitors.
• Evaluation of combinatorial treatment effects of RTKi and TMZ on ATRX-deficient glioma cells.

Main Results:

• Multi-targeted RTK and PDGFR inhibitors demonstrated significant toxicity towards ATRX-deficient high-grade glioma cells.
• Combinatorial treatment with RTKi and TMZ resulted in pronounced toxicity in ATRX-deficient high-grade glioma cells.
• The study identified specific drug classes effective against a common genetic alteration in gliomas.

Conclusions:

• Receptor tyrosine kinase inhibitors (RTKi) show potential as a therapeutic strategy for ATRX-mutated high-grade gliomas.
• Combining RTKi with temozolomide (TMZ) may improve treatment outcomes for GBM patients with ATRX mutations.
• Incorporating ATRX mutation status in clinical trial analysis for RTKi and PDGFR inhibitors is recommended.